Production (Stage)
Zevra Therapeutics, Inc.
ZVRA
$8.65
$0.080.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -91.99M | -105.51M | -89.66M | -66.81M | -49.45M |
| Total Depreciation and Amortization | 6.48M | 6.39M | 5.53M | 3.97M | 2.49M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.13M | 36.10M | 18.93M | 3.15M | 2.57M |
| Change in Net Operating Assets | -13.34M | -6.64M | -4.37M | 3.63M | -1.26M |
| Cash from Operations | -61.72M | -69.67M | -69.57M | -56.06M | -45.66M |
| Capital Expenditure | -99.00K | -- | -72.00K | -244.00K | -267.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -30.40M | -30.40M | -30.40M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -26.31M | -22.16M | 24.37M | 11.44M | 45.63M |
| Cash from Investing | -26.41M | -22.16M | -6.11M | -19.21M | 14.96M |
| Total Debt Issued | 60.07M | 60.07M | 63.70M | 89.70M | 30.77M |
| Total Debt Repaid | -43.50M | -43.13M | -47.86M | -47.66M | -4.88M |
| Issuance of Common Stock | 68.02M | 67.26M | 72.57M | 7.86M | 7.54M |
| Repurchase of Common Stock | -- | -- | 0.00 | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.09M | -2.09M | -2.09M | -2.09M | -- |
| Cash from Financing | 82.50M | 82.11M | 86.32M | 47.81M | 33.43M |
| Foreign Exchange rate Adjustments | 127.00K | 454.00K | 132.00K | 521.00K | -66.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.51M | -9.26M | 10.77M | -26.94M | 2.67M |